摘要
神经退行性疾病的病理生理状况无疑与蛋白质错误折叠有关。错误折叠的蛋白质积累成相对有序的结构,如纤维状细胞内和细胞外淀粉样蛋白,导致组织损伤,从而导致神经元丢失和脑损伤。在这些病理中,蛋白质聚集体的出现表明那些应该适当地协助客户蛋白质折叠的分子伴侣的某些低效或不充分的细胞反应。在这方面,大多数神经退行性疾病的实验模型已经证明分子伴侣的过度表达提供了有效的神经保护。这些分子伴侣的一个子集对应于一组具有肽基脯氨酰异构酶酶活性的蛋白质,即亲免素。后一组的大多数家族成员首先被描述为负责免疫抑制反应,或者他们被报道为与类固醇受体寡聚体中的 HSP90 相关的伴侣复合物的成员。在这篇文章中,我们回顾了分子伴侣与神经退行性疾病之间联系的一些方面,特别是热休克蛋白和亲免蛋白,它们对线粒体的正常功能有影响。本文旨在解决一个领域,该领域代表了一个尚未满足的临床需求,即开发专注于潜在新分子靶点的神经保护分子。
关键词: 亲免蛋白、神经变性、HSP90、FKBP51、FKBP52、亲环蛋白 A。
图形摘要
Current Drug Targets
Title:Role of Mitochondrial Heat-shock Proteins and Immunophilins in Neuro Degenerative Diseases
Volume: 22 Issue: 14
关键词: 亲免蛋白、神经变性、HSP90、FKBP51、FKBP52、亲环蛋白 A。
摘要: Pathophysiologic conditions of neurodegenerative diseases are unquestionably related to protein misfolding. The accumulation of misfolded proteins into relatively ordered structures such as fibrillar intracellular and extracellular amyloids results in tissue lesions that lead to neuronal loss and brain damage. In these pathologies, the occurrence of protein aggregates suggests certain inefficient or insufficient cellular responses of those molecular chaperones that should properly assist the folding of the client proteins. In this regard, most experimental models for neurodegenerative diseases have demonstrated that the overexpression of molecular chaperones provides effective neuroprotection. A subset of these molecular chaperones corresponds to a group of proteins that exhibit peptidylprolyl isomerase enzymatic activity, the immunophilins. Most of the family members of the latter group were first described as being responsible for the immunosuppressive response or they were reported as members of the chaperone complex associated with HSP90 in steroid receptor oligomers. In this article, we review some aspects of the liaison between molecular chaperones and neurodegenerative diseases, in particular heat-shock proteins and immunophilins with demonstrated influence on the proper function of mitochondria. This article is intended to address a field that represents a yet critical unmet clinical need for the development of neuroprotective molecules focused on potentially novel molecular targets.
Export Options
About this article
Cite this article as:
Role of Mitochondrial Heat-shock Proteins and Immunophilins in Neuro Degenerative Diseases, Current Drug Targets 2021; 22 (14) . https://dx.doi.org/10.2174/1389450121999201230204320
DOI https://dx.doi.org/10.2174/1389450121999201230204320 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic:Therapeutic Potential of Peptide Motifs - Part V (Executive Guest Editor: Jean-Claude Herve)]
Current Pharmaceutical Design Silimarin and Cancer
Anti-Cancer Agents in Medicinal Chemistry Exploiting Novel Cell Cycle Targets in the Development of Anticancer Agents
Current Cancer Drug Targets Near-infrared Light Activatable Multimodal Gold Nanostructures Platform: An Emerging Paradigm for Cancer Therapy
Current Cancer Drug Targets The Update of NGAL in Acute Kidney Injury
Current Protein & Peptide Science Transcription Factors as Targets for Cancer Therapy: AP-1 a Potential Therapeutic Target
Current Cancer Therapy Reviews New Approach to Cancer Therapy: The Application of Signal Transduction to Anti-Cancer Drug
Current Medicinal Chemistry - Anti-Cancer Agents Intravesical Bacillus Calmette-Guerin Therapy for Bladder Cancer: Molecular Mechanisms of Action
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Metformin as a Radiation Modifier; Implications to Normal Tissue Protection and Tumor Sensitization
Current Clinical Pharmacology The Shape of the Messenger: Using Protein Structure Information to Design Novel Cytokine-based Therapeutics
Current Pharmaceutical Design Mutant B-Raf Kinase Inhibitors as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Emerging Roles of MicroRNA-22 in Human Disease and Normal Physiology
Current Molecular Medicine Estrogens as Potential Therapeutic Agents in Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Recent Advances in PUVA Photochemotherapy and PDT for the Treatment of Cancer
Current Pharmaceutical Design Novel Mitotic Targets and Their Small-Molecule Inhibitors
Current Cancer Drug Targets Innovations and Improvements in Pharmacokinetic Models Based on Physiology
Current Drug Delivery Cancer Chemoprevention by Dietary Phytochemicals: Promises and Pitfalls
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: “miRNA and Cancer; Computational and Experimental Approaches”)
Current Pharmaceutical Biotechnology Meet Our Editorial Board Member
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Impact of p53 arg72pro SNP on Breast Cancer Risk in North Indian Population
Current Genomics